Navigation Links
Alimera Sciences Reports Third Quarter 2013 Financial Results
Date:11/11/2013

Austria, Portugal and Spain and pending approval in Italy. In addition, Alimera has filed with the Medicines and Healthcare Products Regulatory Agency in the United Kingdom as the Reference Member State for 10 additional European Union country approvals through the Mutual Recognition Procedure.

Non-GAAP Financial Measures Alimera believes the metric "adjusted net loss attributable to common shareholders" and "adjusted net loss per common share" are useful financial measures for investors in evaluating Alimera's performance for the periods presented. Adjusted net loss attributable to common shareholders and adjusted net loss per common share exclude the non-cash warrant valuation adjustment, the non-cash accretion of the beneficial conversion feature and the loss on the early extinguishment.  These metrics, however, are not measures of financial performance under accounting principles generally accepted in the United States (GAAP) and should not be considered a substitute for net loss attributable to common shareholders or net loss per common share in accordance with GAAP and may not be comparable to similarly titled measures reported by other companies. Alimera's management believes that adjusted net loss attributable to common shareholders and adjusted net loss per common share are useful supplements for it and investors to Alimera's GAAP financial information because these measures exclude non-cash or infrequent expenses which management believes are not reflective of Alimera's operating results.  These non-GAAP financial measures also facilitate management's internal comparison to Alimera's historical financial performance and the financial performance of other companies. However, non-GAAP financial measures should only be read in conjunction with financial information reported under GAAP when understanding Alimera's operating performance.  For a reconciliation of net loss attributable to common shareholders to adjusted net loss attributabl
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting
2. Alimera Sciences Reports Second Quarter 2013 Financial Results
3. Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results
4. Alimera Sciences Reports First Quarter 2013 Financial Results
5. Alimera Sciences Secures $20 Million Debt Facility
6. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
7. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
8. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
9. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
10. Alimera Sciences Names European Management Team
11. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
(Date:12/24/2014)... KENNEWICK, Wash. , Dec. 23, 2014 /PRNewswire/ ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that it has ... the Food and Drug Administration ("FDA") for marketing ... to Section 513(f)(2) of the U.S. Food, Drug ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... by Nobel laureate Paul Greengard, Medical Director of The Michael ... Dr. Jennifer L. Warner-Schmidt in New York and colleagues in ... the brain protein called p11 could lead pharmaceutical companies to ... rather than the weeks or even months required by current ...
... 23 Since 1993, when the PLCO trial was started, ... anticipation, as have others. The initial report of the results ... trial -- published last week in the New England Journal ... , * The studies offer conflicting evidence about the possibility ...
Cached Medicine Technology:Key Protein May Lead to Faster Acting Anti-Depression Drugs 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Residents ... Retirement Community, recently showed their generous spirit by ... the Catawba County Parenting Network- Grandparents Raising Grandchildren ... children gathered around the largest Christmas tree on ... presents purchased by residents of the Abernethy Village ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Epigenetics finds ... science research, including oncology, drug discovery, developmental biology, and ... emerging as one of the most widely used techniques ... to GLOBOCAN, the prevalence of cancer is rapidly growing ... cases, 8.2 million cancer deaths, and 32.6 million people ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2
... A new study says that those who suffer from ... blood clots//. ,Earlier studies had found a ... were unaware about the relationship between infections and clotting ... Scientist. ,Researcher Liam Smeeth at the London ...
... is displeased with the way the head of the North Coast ... They said that he has denied telling the Coraki community about ... the community staged a protest against the head of the North ... felt like mushrooms and wanted answers about the Health Department's plans ...
... response to less sales of butter and cheese in Canada, ... 1.7 percent//. This is due to raise in health ... "It should start stabilizing over the next few months. Retail ... absorbed by the market. It means culling cows because we ...
... study conducted by psychologists from Sheffield University most women ... women's attitudes towards sex revealed that women of all ... relationship is wrong. ,The women community despite ... stands do so out of desperation or drunkenness. The ...
... A new study has found that the peels of fruits ... source of potent antioxidants//. So it's better to have a ... those peels that fights against aging and keeps you young. ... foods containing antioxidants have soared in the United States to ...
... Organization (WHO) has called for more funds to combat the ... lives of millions of people at risk in Sudan//. ... at the earliest, the incidence and prevalence of these deadly ... Currently, Sudan is dependent on other nations to help ease ...
Cached Medicine News:Health News:WHO: Lives At Risk In Sudan As Diseases Soar, Call for Funding 2
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
RM-1900 Dermatome developed for reconstructive plastic surgery with E-Type coupling. Dermatome with 50 mm cutting width....
... The New Model C Dermatome - reaching ... switch - Push forward to operate in the ... mode. Autoclavable - the entire instrument and hose ... - Cut grafts in 2-, 3-, or 4-inch ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
Medicine Products: